Drug-drug interactions of newly approved small molecule inhibitors for acute myeloid leukemia

Annals of Hematology
Juan Eduardo Megías-VericatPau Montesinos

Abstract

Several small molecule inhibitors (SMIs) have been recently approved for AML patients. These targeted therapies could be more tolerable than classical antineoplastics, but potential drug-drug interactions (DDI) are relatively frequent. Underestimation or lack of appropriate awareness and management of DDIs with SMIs can jeopardize therapeutic success in AML patients, which often require multiple concomitant medications in the context of prior comorbidities or for the prevention and treatment of infectious and other complications. In this systematic review, we analyze DDIs of glasdegib, venetoclax, midostaurin, quizartinib, gilteritinib, enasidenib, and ivosidenib. CYP3A4 is the main enzyme responsible for SMIs metabolism, and strong CYP3A4 inhibitors, such azoles, could increase drug exposure and toxicity; therefore dose adjustments (venetoclax, quizartinib, and ivosidenib) or alternative therapies or close monitoring (glasdegib, midostaurin, and gilteritinib) are recommended. Besides, coadministration of strong CYP3A4 inducers with SMIs should be avoided due to potential decrease of efficacy. Regarding tolerability, QTc prolongation is frequently observed for most of approved SMIs, and drugs with a potential to prolong the QTc...Continue Reading

References

Mar 10, 2009·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Karl Broich, UNKNOWN Committee for Medicinal Products for Human Use
Jan 5, 2011·The Journal of Antimicrobial Chemotherapy·Livio PaganoNicole Blijlevens
Sep 5, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jorge E CortesMark Levis
Oct 3, 2013·Cancer Chemotherapy and Pharmacology·Catherine DutreixYanfeng Wang
May 20, 2015·Oncotarget·Elisabet CuyàsJavier A Menendez
Apr 1, 2016·Journal of Clinical Pharmacology·Ahmed Hamed SalemShekman L Wong
May 24, 2016·Canadian Pharmacists Journal : CPJ = Revue Des Pharmaciens Du Canada : RPC·James E Tisdale
Jan 20, 2017·Mediterranean Journal of Hematology and Infectious Diseases·Benedetta RambaldiLivio Pagano
Jun 8, 2017·Blood·Eytan M SteinMartin S Tallman
Jun 24, 2017·The New England Journal of Medicine·Richard M StoneHartmut Döhner
Oct 14, 2017·Xenobiotica; the Fate of Foreign Compounds in Biological Systems·Manoj S ChineyAhmed Hamed Salem
Jan 6, 2018·European Journal of Clinical Pharmacology·Kevin J FreiseAhmed Hamed Salem
Jan 13, 2018·Xenobiotica; the Fate of Foreign Compounds in Biological Systems·Zeen TongSekhar Surapaneni
Mar 1, 2018·British Journal of Clinical Pharmacology·M Naveed ShaikRobert R LaBadie
Mar 22, 2018·Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners·Eris Tollkuci
Jun 5, 2018·The New England Journal of Medicine·Courtney D DiNardoHagop M Kantarjian
Apr 5, 2019·American Journal of Hematology·Bruno C MedeirosDaniel A Pollyea
Apr 24, 2019·European Journal of Clinical Pharmacology·David DaiBin Fan
Jun 15, 2019·Journal of the National Comprehensive Cancer Network : JNCCN·Martin S TallmanNdiya Ogba

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anthelmintics

Anthelmintics or antihelminthics are a group of antiparasitic drugs that expel parasitic worms (helminths) and other internal parasites from the body by either stunning or killing them and without causing significant damage to the host. Discover the latest research on anthelmintics here.

Acute Myeloid Leukaemia & RNA

Acute myeloid leukaemia (AML) is a common hematological type of cancer. As the population ages, there has been a rise in the frequency of AML. RNA expression has been used to see if there are different genetic profiles that exist within AML and whether these may underpin the variations in survival rates. Here is the latest research on AML and RNA.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.